| Objective:With the understanding of the pathogenesis of respiratory diseases continues to improve, gastroesophageal reflux (gastro-esophageal reflux disease, GERD) and respiratory diseases contact has gradually been recognized, including bronchial asthma (bronchial asthma, BA) (referred to as asthma) and gastroesophageal reflux (GERD) in combination widespread attention. Bronchial asthma is a respiratory disease, is caused by various inflammatory cells, inflammatory mediators and cytokines involved in chronic non-specific inflammation of airways disease; gastroesophageal reflux (GERD) is a common digestive system, mainly as acid reflux, heartburn, chest pain and other symptoms. Stomach contents back into the airway through the esophagus can cause or aggravate asthma, and asthma, gastroesophageal reflux may also add to recent years, combined with bronchial asthma patients with gastroesophageal reflux improvement of living standards gradually increased, causing widespread concern in the medical profession. Esomeprazole enteric-coated tablets (esomeprazole) (Nexium) is a new generation of treatment of gastric reflux proton pump inhibitors, is the L-isomer of omeprazole, reduce acid reflux by acid suppression in has its unique treatment of GERD. Nexium in the treatment of GERD, but also the associated symptoms of bronchial asthma treatment and improvement. Compared with omeprazole in this topic and further outlook Cha Aisuo Merah yl enteric-coated tablets (Nexium) in the treatment of bronchial asthma (the asthma), gastroesophageal reflux combination of clinical efficacy.Methods:62 patients with asthma and GERD were randomly divided into the test group (mean age 41.5) and the control group (mean age 42), two groups of agents in the treatment of asthma, based on the trial 31 patients plus Nexium 40mg orally once a day, plus the control group 31 cases of oral omeprazole 40mg once daily; course of eight weeks. Records of patients before and after medication heartburn, acid back, chest burning and other changes in symptom scores, according to the value of symptom scores and endoscopic examination results declined compared the efficacy of treatment of gastroesophageal reflux; while observing the changes in asthma symptoms; measuring a second force expiratory volume (FEV1), peak expiratory flow (PEF), to evaluate changes in lung function before and after treatment.Results:(1) After taking the test group Id,3d,7d,14d,28d GERD symptom scores decreased values were 13.8≈6.5,10.7±6.8,9.8±5.5,6.5±5.5,5.6±4.7; the control group were 14.3±5.4,14.2±5.5,13.8±5.3,13.7±5.8,7.9±5.0, the difference between the two was significant (P <0.05). After eight weeks of endoscopy review, the experimental group and control group the healing rate of esophageal mucosa damage to 70.9% and 64.5%, the effective rate was 93.5% and 87.1%, experimental group was higher, but there were no significant differences (P> 0.05). (2) After eight weeks of the study group net increase in lung function PEVl value 0.628±0.401, while the control group was 0.379±0.298, the difference was significant (P<0.05). PEF peak expiratory flow rate test group net increase in value of 1.037±0.421, while the control group was 0.706±0.325, the difference was significant (P<0.05). Asthma test group the total effective rate was 90.3％improvement of the control group, the total effective rate of asthma improved 77.4%, the difference was significant (P<0.05).Conclusion:Esomeprazole significantly improve symptoms of asthma with GERD patients to reduce airway hyperresponsiveness, improve lung function, quality of life.
|
PDF Full Text Request